Fetal fibronectin (fFN) antibody and antigen (Recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-h-fFN-Ag01	Recombinant human FN1/fFN/FN Protein	3090
GMP-h-fFN-Ab01	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb)	1953
GMP-h-fFN-Ab02	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb)	1953
GMP-h-fFN-Ab03	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb)	1953
GMP-h-fFN-Ab04	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb)	1953
GMP-h-fFN-Ab05	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-h-fFN-Ag01
Product Name	Recombinant human FN1/fFN/FN Protein
Target/Biomarker	Fetal fibronectin (fFN)
Alias of Target/Biomarker	CIG, ED-B, FINC, FN, FNZ, GFND, GFND2, LETS, MSF, SMDCF
Expression platform	mammalian
Isotypes	Recombinant Antigen
Bioactivity validation	Fetal fibronectin (fFN) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in fFN level test of Fertility (premature delivery) and related syndrome evaluation.
Tag	His
Products description	Recombinant human FN1/fFN/FN Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-fFN-Ab01, GMP-h-fFN-Ab02, GMP-h-fFN-Ab03, GMP-h-fFN-Ab04, GMP-h-fFN-Ab05
Product Name	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb)
Target/Biomarker	Fetal fibronectin (fFN)
Alias of Target/Biomarker	CIG, ED-B, FINC, FN, FNZ, GFND, GFND2, LETS, MSF, SMDCF
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Fetal fibronectin (fFN) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in fFN level test of Fertility (premature delivery) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human FN1/fFN/FN mouse monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

GeneMedi provides 5 kinds of Anti-human fFN mouse monoclonal antibody(mAb): GMP-h-fFN-Ab01; GMP-h-fFN-Ab02; GMP-h-fFN-Ab03; GMP-h-fFN-Ab04; GMP-h-fFN-Ab05. Our R&D department demonstrated that our Anti-human fFN mouse monoclonal antibody pair has a large linear range and good sensitivity against the GMP-h-fFN-Ag01. Below is the result of GeneMedi's GMP-h-fFN-Ab pair validation with GMP-h-fFN-Ag01 in ELISA. We highly recommend the Ab&Ag to you.

Figure 1: GeneMedi's GMP-h-fFN-Ab pairs are validated to detect the GMP-h-fFN-Ag01 in ELISA.

   EC50 [Ab01 (capture)-Ab02 (detect)]= 76.68  ppb;

   EC50 [Ab05 (capture)-Ab02 (detect) ]= 130.7  ppb;

   EC50 [Ab03 (capture)-Ab01 (detect) ]= 97.78  ppb;

   EC50 [Ab04 (capture)-Ab01 (detect) ]= 79.94  ppb;

   EC50 [Ab04 (capture)-Ab05 (detect) ]= 530.8  ppb.

Click to get more Data / Case study about the product.

Target/Biomarker information

Fetal fibronectin (fFN) is a protein produced at the boundary between the amniotic sac (which surrounds the baby) and the lining of the mother’s uterus (the decidua). Fetal fibronectin is largely confined to this junction and is thought to help “glue” or maintain the integrity of the boundary between the amniotic sac and the lining of the uterus. A fetal fibronectin test detects fFN in vaginal fluid to help predict the short-term risk of premature delivery. According to the American College of Obstetricians and Gynecologists (ACOG), a normal pregnancy is about 40 weeks, with a woman going into labor between 37 and 42 weeks. A preterm delivery is one that occurs between 20 and 37 weeks of pregnancy. fFN is found in vaginal fluids early in pregnancy because of the normal growth and establishment of tissues at the junction between the amniotic sac and uterus, with levels falling when this phase is complete. fFN is also found in fluids from the vagina after 36 weeks when it is often released into vaginal fluids as the body gets ready for childbirth. However, fFN should not be detectible between 22 and 35 weeks of pregnancy. Elevated levels during this period reflect a disturbance at the junction between the amniotic sac and the lining of the uterus. Elevated fFN in vaginal fluids during these weeks of pregnancy has been associated with an increased risk of preterm labor and delivery. Many pregnant women experience symptoms that suggest preterm labor. These may include uterine contractions, changes in vaginal discharge, backaches, abdominal discomfort, pelvic pressure, cramping, and dilation of the cervix. However, not all symptomatic women will actually have a preterm delivery. The majority will go on to deliver at term. Unfortunately, while premature births can have successful endings, serious complications are possible when a baby leaves the womb early. Premature babies frequently have difficulty breathing and feeding. Their lungs and other organs are immature and do not function normally, and the strain on them can cause persistent health problems. The more premature the newborn, the more likely it is that he or she will experience complications. If a healthcare practitioner thinks that a woman might deliver early, she will consider treatments designed to delay delivery. These treatments can have unwanted side effects, however, so knowing whether or not a woman is likely to deliver prematurely helps in the decision on the best course of action. The fFN test is a relatively noninvasive tool that can help distinguish between those women who are likely to deliver shortly and those who are not.

About GDU